Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, human epidermal growth factor receptor 2 -negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||22/07/2020|
|Rapid review completed||03/09/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alpelisib (Piqray®) compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||30/09/2020|
|Pre-submission consultation with Applicant||Scheduled|
|Current Status||Pre-submission consultation scheduled|